Graphite Capital has sold Beacon, the leading global data and workflow platform for the life sciences R&D community, to Corten Capital. Beacon is an essential decision-support tool for developers of complex therapeutics, used by senior scientists at the world’s largest pharmaceutical and biotech companies to inform high-value R&D investment decisions. The business has recently been carved out of Hanson Wade, a leading service provider to the life sciences sector. The sale is expected to complete by the end of June 2026 and will deliver a cash return of around 4x Graphite’s investment in Hanson Wade as a whole, with the firm retaining the Hanson Wade conference business for further value growth.
Under Graphite’s ownership, Beacon’s annualised recurring revenues have grown thirteenfold, supported by significant investment in technology, data and commercial capability.
